A research and development decision model for pharmaceutical industry: case of China
通过层次决策模型评估中国制药行业的技术领域、发展战略和创新资源，发现国内中小企业是首选创新主体，但外资跨国公司紧随其后，且重组治疗蛋白、重组疫苗和单克隆抗体技术将影响创新资源优先级。
This paper evaluates prospective technology areas, development strategies, and various innovation resources in China's pharmaceutical sector through the use of a hierarchical decision model. The results indicate that although domestic SMEs are the major preferred innovation alternative, it is followed closely by foreign MNCs. The sensitivity analysis indicates that the effectiveness of policy decisions are influenced by certain high technology areas. Recombinant therapeutic proteins, recombinant vaccines, and monoclonal antibody technologies are identified as the major areas that will influence the priority of innovation resources. The research crafts a research framework to formulate innovation strategies in dealing with the uncertainties of technology development and policy decisions in the biopharmaceutical industry.